Hydrodilatation: a comparison between diabetics and non-diabetics with adhesive capsulitis.

IF 2 3区医学 Q2 ORTHOPEDICS

International Orthopaedics Pub Date : 2024-12-16 DOI:10.1007/s00264-024-06392-1

Jason Derry Onggo, Mehek Gupta, Eugene Low, Lester Teong Jin Tan, Keng Thiam Lee, Sean Wei Loong Ho, Jegathesan T

{"title":"Hydrodilatation: a comparison between diabetics and non-diabetics with adhesive capsulitis.","authors":"Jason Derry Onggo, Mehek Gupta, Eugene Low, Lester Teong Jin Tan, Keng Thiam Lee, Sean Wei Loong Ho, Jegathesan T","doi":"10.1007/s00264-024-06392-1","DOIUrl":null,"url":null,"abstract":"Purpose: The primary aim of this retrospective study is to compare the short and medium-term outcomes for shoulder hydrodilatation for treatment of shoulder AC between diabetic and non-diabetic patients, to evaluate if there were better outcomes amongst non-diabetic patients.Methods: Patients with clinical or radiological diagnosis of AC and who underwent fluoroscopic guided shoulder hydrodilatation in our local institution from January 2021 to June 2022 were included in this study. Clinical outcomes were measured with visual analog scale (VAS) for pain and passive range of motion consisting of forward flexion (FF) and external rotation (ER) at pre-hydrodilatation, one month and six months post hydrodilatation.Results: A total of 163 shoulders were included, corresponding to 156 patients consisting of 47 diabetics, 109 non-diabetics and seven bilateral shoulders (3 diabetics and 4 non-diabetics). At the time of presentation, there was no significant difference in VAS, FF or ER between diabetics and non-diabetics. From pre-hydrodilatation to 1-month post-hydrodilatation and one month to six months post-hydrodilatation, there was significant improvement in VAS, FF and ER for both groups. Comparing diabetics vs. non-diabetics, the non-diabetic group had significantly better FF (p < 0.01) at one month post hydrodilatation. At 6 months post-hydrodilatation, non-diabetic group also had significantly better outcomes including VAS score (p = 0.02), FF (p < 0.01) and ER (p = 0.02).Conclusion: Hydrodilatation is an effective treatment option in the short and medium term in both diabetics and non-diabetics with adhesive capsulitis, with good relief of pain and improvement in shoulder range of motion. Diabetic patients have significantly less improvement in range of motion and pain compared to non-diabetics at six months post hydrodilatation.","PeriodicalId":14450,"journal":{"name":"International Orthopaedics","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Orthopaedics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00264-024-06392-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The primary aim of this retrospective study is to compare the short and medium-term outcomes for shoulder hydrodilatation for treatment of shoulder AC between diabetic and non-diabetic patients, to evaluate if there were better outcomes amongst non-diabetic patients.

Methods: Patients with clinical or radiological diagnosis of AC and who underwent fluoroscopic guided shoulder hydrodilatation in our local institution from January 2021 to June 2022 were included in this study. Clinical outcomes were measured with visual analog scale (VAS) for pain and passive range of motion consisting of forward flexion (FF) and external rotation (ER) at pre-hydrodilatation, one month and six months post hydrodilatation.

Results: A total of 163 shoulders were included, corresponding to 156 patients consisting of 47 diabetics, 109 non-diabetics and seven bilateral shoulders (3 diabetics and 4 non-diabetics). At the time of presentation, there was no significant difference in VAS, FF or ER between diabetics and non-diabetics. From pre-hydrodilatation to 1-month post-hydrodilatation and one month to six months post-hydrodilatation, there was significant improvement in VAS, FF and ER for both groups. Comparing diabetics vs. non-diabetics, the non-diabetic group had significantly better FF (p < 0.01) at one month post hydrodilatation. At 6 months post-hydrodilatation, non-diabetic group also had significantly better outcomes including VAS score (p = 0.02), FF (p < 0.01) and ER (p = 0.02).

Conclusion: Hydrodilatation is an effective treatment option in the short and medium term in both diabetics and non-diabetics with adhesive capsulitis, with good relief of pain and improvement in shoulder range of motion. Diabetic patients have significantly less improvement in range of motion and pain compared to non-diabetics at six months post hydrodilatation.

查看原文本刊更多论文

水扩张：患有粘连性囊炎的糖尿病患者与非糖尿病患者之间的比较。

目的：本回顾性研究的主要目的是比较糖尿病患者和非糖尿病患者接受肩关节水扩张术治疗肩关节积液的短期和中期疗效，以评估非糖尿病患者是否有更好的疗效：本研究纳入了 2021 年 1 月至 2022 年 6 月期间在本院接受透视引导下肩关节水扩张术的临床或放射学诊断为 AC 的患者。临床结果通过视觉模拟量表（VAS）测量肩关节水扩张术前、术后一个月和六个月的疼痛和被动活动范围，包括前屈（FF）和外旋（ER）：共纳入 163 个肩关节，对应 156 名患者，包括 47 名糖尿病患者、109 名非糖尿病患者和 7 名双侧肩关节患者（3 名糖尿病患者和 4 名非糖尿病患者）。就诊时，糖尿病患者和非糖尿病患者的 VAS、FF 或 ER 均无明显差异。从血液透析前到血液透析后 1 个月，以及血液透析后 1 个月到 6 个月，两组患者的 VAS、FF 和 ER 均有明显改善。比较糖尿病患者和非糖尿病患者，非糖尿病组的 FF 明显更好（p 结论：水张术对糖尿病患者和非糖尿病患者都有很好的疗效：对于患有粘连性肩关节囊炎的糖尿病患者和非糖尿病患者来说，水扩张术都是一种短期和中期有效的治疗方法，能很好地缓解疼痛并改善肩关节的活动范围。与非糖尿病患者相比，糖尿病患者在水压扩张术后六个月的活动范围和疼痛改善程度明显较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Orthopaedics 医学-整形外科

CiteScore

5.50

自引率

7.40%

发文量

360

审稿时长

1 months

期刊介绍： International Orthopaedics, the Official Journal of the Société Internationale de Chirurgie Orthopédique et de Traumatologie (SICOT) , publishes original papers from all over the world. The articles deal with clinical orthopaedic surgery or basic research directly connected with orthopaedic surgery. International Orthopaedics will also link all the members of SICOT by means of an insert that will be concerned with SICOT matters. Finally, it is expected that news and information regarding all aspects of orthopaedic surgery, including meetings, panels, instructional courses, etc. will be brought to the attention of the readers. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Reports of animal experiments must state that the "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed, as well as specific national laws (e.g. the current version of the German Law on the Protection of Animals) where applicable. The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfil the above-mentioned requirements.